Prescient Therapeutics - Extension of Share Purchase Plan

Key points

• Extension of Share Purchase Plan to raise up to $7 million
• Funds will advance PTX-100 development
• New closing date set for Tuesday, 15 September 2026

Full summary

Prescient Therapeutics Limited, a clinical-stage oncology company, has extended the closing date of its Share Purchase Plan (SPP) to allow shareholders more time to participate. The SPP, targeting to raise up to $7 million, will now close on Tuesday, 15 September 2026 at 5pm (AEST). The funds raised will support the advancement of PTX-100, a targeted cancer therapy, beyond the upcoming Dose Optimisation Committee meeting in December 2026. Eligible shareholders can apply for new shares at a discount of 18.8% to the volume weighted average price over the past 10 trading days. Shareholders can request their personalized SPP form from the provided link.